EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Envarsus

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
IB/0030	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	18/01/2023		SmPC and PL	

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

IA/0029/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	11/10/2022	n/a		
IB/0028/G	This was an application for a group of variations. C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference	25/07/2022		SmPC, Annex II, Labelling and PL	C.I.3.a - To update sections 4.4 and 4.5 of the SmPC and section 2 of the PL, to implement the signal recommendation on drug interaction with cannabidiol leading to systemic calcineurin inhibitors and mTOR inhibitors serum levels increased and toxicity (EPITT 19614). C.I.2.a - To update of sections 4.4, and 4.5 of the SmPC on the interaction with CYP3A4. Section 4.5 of the SmPC is also updated to include impact of direct acting antiviral therapy. In addition, to update section 4.8 of the SmPC to

	product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				add posterior reversible encephalopathy syndrome as an adverse reaction and update the SOC for febrile neutropenia from 'General disorders and administration site conditions' to 'Blood and lymphatic system disorders'.
PSUSA/2839/202103	Periodic Safety Update EU Single assessment - tacrolimus (systemic formulations)	16/12/2021	16/02/2022	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2839/202103.
N/0027	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	09/12/2021	16/02/2022	PL	
IA/0024/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	04/06/2021	n/a		
IAIN/0023/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.7 - Administrative change - Deletion of manufacturing sites	14/04/2021	n/a		

IB/0022/G	This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size	15/01/2021	n/a		
N/0021	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	17/11/2020	19/02/2021	PL	
IA/0020	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	19/06/2020	n/a		
IA/0019	B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	25/05/2020	n/a		
IA/0018/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test	25/05/2020	n/a		

	procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
IB/0016/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation	26/02/2020	19/02/2021	SmPC and PL	
IA/0017/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised B.II.f.1.e - Stability of FP - Change to an approved stability protocol	07/02/2020	n/a		

IAIN/0015	B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer	28/06/2019	n/a		
R/0014	Renewal of the marketing authorisation.	28/03/2019	06/06/2019	SmPC	
PSUSA/2839/201803	Periodic Safety Update EU Single assessment - tacrolimus (systemic formulations)	13/12/2018	12/02/2019		Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2839/201803.
IB/0013/G	This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS	10/10/2018	n/a		
II/0008/G	This was an application for a group of variations. B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new	14/12/2017	n/a		

	specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.i - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Where there is no monograph in the European/National Ph. for the AS, a change in specification from in-house to a non-official/third country Ph. B.I.b.1.i - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Where there is no monograph in the European/National Ph. for the AS, a change in specification from in-house to a non-official/third country Ph. B.I.b.1.i - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Where there is no monograph in the European/National Ph. for the AS, a change in specification from in-house to a non-official/third country Ph. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in				

	imprints, bossing or other markings				
N/0011	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	05/05/2017	12/02/2019	PL	
IAIN/0010	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	24/04/2017	n/a		
IA/0009	A.7 - Administrative change - Deletion of manufacturing sites	21/02/2017	11/04/2017	Annex II and PL	
IB/0007	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	11/04/2016	11/04/2017	SmPC, Labelling and PL	
IB/0006/G	This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS -	21/12/2015	n/a		

	Tightening of in-process limits				
PSUSA/2839/201503	Periodic Safety Update EU Single assessment - tacrolimus (systemic formulations)	03/12/2015	n/a		PRAC Recommendation - maintenance
PSUSA/10337/201501	Periodic Safety Update EU Single assessment - tacrolimus (systemic formulations)	10/09/2015	n/a		PRAC Recommendation - maintenance
IAIN/0005	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	20/08/2015	14/12/2015	Annex II and PL	
IAIN/0001/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring	22/12/2014	14/12/2015	SmPC, Annex II and PL	